Regulating the cancer-inducing potential of non-steroidal anti-inflammatory drugs: Some lessons from the 1970s and 1980s

Social Science and Medicine

Volumn 46, Issue 1, 1998, Pages 39-51

  Abraham, John ^a  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

Author keywords

Carcinogenicity; Drug regulation; Non steroidal anti inflammatory drugs; Scientific standards

Indexed keywords

BENOXAPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; SUPROFEN; ZOMEPIRAC;

ARTICLE; CARCINOGEN TESTING; CARCINOGENICITY; GOVERNMENT; HUMAN; RISK ASSESSMENT; UNITED KINGDOM; UNITED STATES;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARCINOGENICITY TESTS; DRUG AND NARCOTIC CONTROL; GREAT BRITAIN; HISTORY, 20TH CENTURY; MALE; MICE; NAPROXEN; PROPIONIC ACIDS; RATS; SUPROFEN; TOLMETIN; UNITED STATES;

EID: 0031983387     PISSN: 02779536     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0277-9536(97)00133-0     Document Type: Article

References (80)

1. Association of the British Pharmaceutical Industry (ABPI) (1977) Guidelines for Preclinical and Clinical Testing of New Medicinal Products Part I - Laboratory Investigations. ABPI, London.
2. Barnes, J. M. and Denz, F. A. (1954) Experimental methods used in determining chronic toxicity: critical review. Pharmacological Reviews 6, 191-242.
3. Bland, J. M., Jones, D. R., Bennett, S., Cook, D. G., Haines, A. P. and MacFarlane, A. J. (1985) Is the clinical trial evidence about new drugs statistically adequate? British Journal of Clinical Pharmacology 19, 155-160.
4. Chetley, A. (1995) Problem Drugs. Zed Books, London.
5. Collier, J. (1989) The Health Conspiracy. Century, London.
6. Day, M. (1996) U.S. drug safety regime "flawed". New Scientist 9 November, 10.
7. DHSS (1978) MLX 108. Consultation Document - Notes for Guidance on Carcinogenicity Testing of Medicinal Products. DHSS, London.
8. DHSS (1979) MAIL 24. Notes for Guidance on Carcinogenicity Testing on Medicinal Products. DHSS, London.
9. Dista (1980a) Opren data sheet, April.
10. Dista (1980b) Opren data sheet, August.
11. Eli Lilly (1982a) Oraflex package insert, May.
12. Eli Lilly (1982b) Oraflex brochure for U.S. physicians.
13. Eli Lilly (1984) General Commentary on the Long-Term Rat Study on Benoxaprofen. Lilly Research Laboratories, Toxicology Division, 22 February, Greenfield, IN.
14. Food and Drug Administration (FDA) (1976a) IBT study carried out for Syntex. Memo by M. Hein and A. Gross, 10 August.
15. FDA (1976b) Naproxen chronic toxicity/carcinogenesis study by IBT. Memo by C. King, 15 July.
16. FDA (1976c) Summary of inspectional findings made in connection with 22-month oral administration study conducted in rats by IBT on naproxen by A. Gross and M. Hein, 20 July.
17. FDA (1976 d) IBT study on naproxen. Memo by M. Hein and A. Gross, 10 August.
18. FDA (1976e) Inspection of IBT/Naprosyn. Memo, 6 July.
19. FDA (1976f) Naproxen. Memo by F. Kelsey, 20 July.
20. FDA (1976 g) Letter from R. Crout, Director of Bureau of Drugs, FDA to H. Anderson, Syntex Corporation, 5 August.
21. FDA (1976 h) Syntex-naprosyn. Memo, 30 August.
22. FDA (1976i) Pharmacology review of naproxen, 30 August.
23. FDA (1977a) Review and evaluation of the Syntex submission in response to our notice of hearing to withdraw the NDA on Naprosyn by A. Gross, 14 January.
24. FDA (1977b) Review of data submitted in relation to notice of hearing for naproxen. Memo by M. Hein, 14 January.
25. FDA (1979a) Supplemental pharmacology review no. 7, 10 April.
26. FDA (1979b) Supplemental pharmacology review no. 2 by M. Hein, 25 October.
27. FDA (1979c) Non-steroidal anti-inflammatory, analgesic agents. Memo by J. Harter, 9 February.
28. FDA (1979 d) Memo by M. J. Finkel, Associate Director for New Drug Evaluation, 23 October.
29. FDA (1980a) Pharmacology review no.8 by M. Hein, 20 March.
30. FDA (1980b) Statistical review and evaluation by R. Stein, 19 September.
31. FDA (1980c) Supplemental pharmacology review by M. Hein, 20 May.
32. FDA (1980 d) Memo of meeting between McNeil Laboratories and FDA, 16 October.
33. FDA (1980e) Memo by M. J. Finkel, Associate Director of New Drug Evaluation, 7 October.
34. FDA (1980f) Supplementary pharmacology review by M. Hein, 7 July.
35. FDA (1980 g) Addendum by D. J. Richman to FDA supplementary pharmacology review by M. Hein, 7 July.
36. FDA (1981a) Certified letter of non-approval of the benoxaprofen NDA by Marion Finkel, 25 February.
37. FDA (1981b) Memo of meeting between McNeil Laboratories and FDA, 23 November.
38. FDA (1982a) Pharmacology review no. 10 by S. Stolzenberg, 1 March.
39. FDA (1982b) Certified letter to Lilly of approval for benoxaprofen by Finkel, April 19.
40. FDA (1982c) Adrenal tumour and combinations. Memo of meeting with McNeil, 5 February.
41. FDA (1983a) Memo of meeting with Lilly, 21 December.
42. FDA (1983b) FDA critique of Dr N. Adrian Gross: review of zomepirac chronic studies. Letter from M. Novitch, Deputy Commissioner of FDA, to Congressman Ted Weiss, 21 July.
43. FDA (1983c) Memo of meeting with McNeil, 4 March.
44. FDA (1984) Pharmacology review no. 14, 10 April.
45. FDA (1985a) Memo of meeting between J. Harter and D. Pease of the FDA with Max Talbott of Lilly, 18 July.
46. FDA (1985b) Review and evaluation of pharmacology and toxicology data by C. Chen, 18 July.
47. FDA (1985c) Review and evaluation of pharmacology and toxicology data by C. Chen, 20 March.
48. FDA (1985 d) Addendum by D. J. Richman to FDA review and evaluation of pharmacology and toxicology data by C. Chen, 18 July.
49. FDA (1985e) Group leader summary by J. Harter, 25 June.
50. FDA (1985f) Memo of meeting with McNeil and Ortho, 25 November.
51. FDA Arthritis Advisory Committee (1983) Discussion of Zomax, 19 August.
52. Gross, A. (1987) Report to Congress on Suprol.
53. Interagency Regulatory Liason Group (IRLG)(1979) Scientific basis for identification of potential carcinogens and estimation of risks. .Journal of the National Cancer Institute 63, 241-268.
54. International Conference on Harmonisation of Technical Standards for Medicinal Products (ICH) (1995) The status of S1B (carcinogenicity guidelines). In ICH3 Closing Report, Status of Harmonisation, ICH, Yokohama, Japan.
55. Maugh, T. H. (1978) Chemical carcinogens: the scientific basis for regulation. Science 201, 1200-1205.
56. McNeil (1980) Zomax package insert, October.
57. McNeil (1986) Suprol package insert, April.
58. Millstone, E. (1986) Food Additives: Taking the Lid Off what we Really Eat. Penguin, Harmondsworth.
59. Ortho-Cilag (1981) Zomax data sheet, April.
60. Ortho-Cilag (1984) Suprol data sheets, ABPI Compendia.
61. Personal communication (1995a) Telephone interview with Dr Berridge, preclinical assessor at the Medicines Control Agency, Department of Health, U.K., November.
62. Personal communication (1995b) Interview with Dr Schmidt at BfArM, the German drug regulatory authorities, November.
63. Personal interview (1988) Dr Kerausitis, FDA Medical Officer, 3 November.
64. Pharmaceutical Manufacturers' Association (PMA) (1977) Guidelines for the Assessment of Drug and Medical Device Safety in Animals. PMA, Washington, DC.
65. Salsburg, D. (1983) The lifetime feeding study in mice and rats - an examination of its validity as a bioassay for human carcinogens. Fundamental and Applied Toxicology 3, 63-67.
66. Scrip (1991) US anti-inflammatory market $4 billion in 1995? No. 1632, 10 July.
67. Scrip (1992) UK arthritis costs estimated. No. 1708, 10 April.
68. Stevenson, D. E. (1979) Current problems in the choice of animals for toxicity testing. Journal of Toxicology and Environmental Health 5, 9-15.
69. Syntex (1975-1981) Naprosyn data sheets.
70. U.S. Congress (1977) Hearings before the Subcommittee on Health and Scientific Research of the Senate Committee on Human Resources. In Preclinical and Clinical Testing by the Pharmaceutical Industry, 1977, Part IV, 10 March. U.S. Congress, Washington, DC.
71. U.S. Congress (1982) Hearings before a Subcommittee of the Committee on Government Operations House of Representatives 97th Congress. In The Regulation of New Drugs by the Food and Drug Administration: The New Drug Review Process, 3-4 August. U.S.G.P.O., Washington, DC.
72. U.S. Congress (1983a) Hearings of the Intergovernmental Relations and Human Resources Subcommittee of the House of Representatives 1983. In FDA's Regulation of Zomax, 26-27 April. U.S. Congress, Washington, DC.
73. U.S. Congress (1983b) 31st Report, House Committee on Government Operations. In FDA's Regulation of Zomax. U.S.G.P.O, Washington, DC.
74. U.S. Congress (1987) Hearings before a Subcommittee of the House Committee on Government Operations. In FDA's Regulation of the New Drug Suprol, 27 May. U.S. Congress, Washington, DC.
75. Veitch, A. (1987) Arthritis drug linked with cancer. Guardian, 22 June, 5.
76. Wieringa, N. F.et al. (1992) The gap between legal rules and practice in advertising non-registered pharmaceutical products. Social Science & Medicine 35, 1497-1504.
77. Woods, R. T. and Britton, P. G. (1985) Clinical Psychology with the Elderly. Croom Helm, Kent.
78. Worden, A. N. (1974) Toxicological methods. Toxicology 2, 359-370.
79. World Health Organisation (WHO) (1969) Principles for the Testing and Evaluation of Drugs for Carcinogenicity. Technical Report Series 426, WHO, Geneva.
80. World Health Organisation (WHO) (1974) Assessment of the Carcinogenicity and Mutagenicity of Chemicals. Technical Report Series No. 546, WHO, Geneva.